Last edition
News about "chronic obstructive pulmonary disease (COPD) "
Zydus Launches REVAHALE, India's First Once-Daily Nebulised LAMA for COPD
Zydus launches REVAHALE (revefenacin), India’s first once-daily nebulised LAMA for COPD, offering sustained 24-hour bronchodilation through nebulised delivery.
Chronic Obstructive Pulmonary Disease (COPD) | 11/08/2026 | By News Bureau
CHMP Recommends AstraZeneca's Trixeo for EU Approval in Asthma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended EU approval of AstraZeneca's Trixeo for asthma maintenance, backed by positive phase 3 KALOS and LOGOS trial results.
Chronic Obstructive Pulmonary Disease (COPD) | 25/07/2026 | By News Bureau | 137
Lupin Partners with ERN to Launch Luforbec in Spain
Lupin has partnered with ERN to launch Luforbec (beclometasone/formoterol) pMDI in Spain, combining Lupin’s respiratory expertise and advanced inhaler manufacturing capabilities with ERN’s strong market presence to expand access to high-quality respiratory care for patients across the country.
Chronic Obstructive Pulmonary Disease (COPD) | 08/06/2026 | By News Bureau | 108
China Approves Trelegy Ellipta for Uncontrolled Asthma
China has approved Trelegy Ellipta for adults with uncontrolled asthma, extending its use beyond COPD and making it the only single-inhaler triple therapy for both conditions in the country.
Chronic Obstructive Pulmonary Disease (COPD) | 27/01/2026 | By News Bureau | 291
Generate:Biomedicines to Begin Phase 3 Trials of AI-Engineered Asthma Antibody GB-0895
Generate:Biomedicines is set to begin its first global Phase 3 trials for GB-0895, an AI-engineered long-acting anti-TSLP antibody for patients with severe, uncontrolled asthma. The SOLAIRIA-1 and SOLAIRIA-2 studies will evaluate the therapy in about 1,600 patients, marking a key milestone for programmable biology in respiratory care.
Chronic Obstructive Pulmonary Disease (COPD) | 02/12/2025 | By Dineshwori | 399
GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide
Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.
Chronic Obstructive Pulmonary Disease (COPD) | 29/10/2025 | By Dineshwori | 319
Fosun Pharma Industrial has signed a global License Agreement with Expedition Therapeutics Inc., granting the US-based biotechnology company the rights to develop, manufacture, and commercialise its investigational respiratory drug XH-S004 in all regions worldwide, excluding the Chinese Mainland, Hong Kong SAR, and Macau SAR.
Chronic Obstructive Pulmonary Disease (COPD) | 13/08/2025 | By Dineshwori | 371
Merck to Acquire Verona Pharma for USD 10 Billion to Expand Cardio-Pulmonary Portfolio
Merck, through a subsidiary, will acquire Verona Pharma for USD 107 per American Depository Share (ADS), each of which represents eight shares of Verona Pharma, for a total transaction value of approximately USD 10 billion.
Chronic Obstructive Pulmonary Disease (COPD) | 10/07/2025 | By Dineshwori | 493
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy